Stockscreener 앱 받기
125.29
0.82%
-1.03
시간 외 거래:
125.44
0.15
+0.12%
전일 마감가:
$126.32
열려 있는:
$126.28
하루 거래량:
4.92M
Relative Volume:
0.80
시가총액:
$217.86B
수익:
$43.84B
순이익/손실:
$13.90B
주가수익비율:
15.72
EPS:
7.9725
순현금흐름:
$6.92B
1주 성능:
-2.53%
1개월 성능:
+1.17%
6개월 성능:
-6.30%
1년 성능:
+7.74%
1일 변동 폭
$125.21
$127.56
1주일 범위
$125.21
$129.85
52주 변동 폭
$110.86
$140.84
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
ABT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
125.29 | 219.65B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.57 | 146.79B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
365.95 | 140.23B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.97 | 130.80B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.98 | 49.16B | 5.88B | 1.34B | 799.60M | 2.3489 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Seven States Join Abbott Infant Formula FCA Lawsuit, Alleging Years of Violations and Cover-Ups - USA Herald
Abbott Defends Glucose Monitor Patents In Sinocare Fight - Law360
The US Rollout of MiniMed 780G With Abbott's Sensor May Lift MDT Stock - sharewise.com
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Can Abbott Laboratories stock weather global recessionForecast Cut & AI Based Buy and Sell Signals - Newser
States Hit Abbott With FCA Suit Over Infant Formula Recall - Law360
7 deaths linked to faulty blood glucose monitors as FDA issues safety warning - Fox Business
Seven deaths possibly linked to malfunctioning glucose monitors - USA Today
Medtronic begins U.S. commercial launch of the MiniMed™ 780G system with the Instinct sensor, made by Abbott - Medtronic
Here's Why We Think Abbott Laboratories (NYSE:ABT) Is Well Worth Watching - Yahoo Finance
This Top Dividend King Just Became an Even Better Buy - AOL.com
Immunoassay Market to Get an Explosive Growth | BD, Abbott, Sysmex Corporation - openPR.com
Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now - ts2.tech
Abbott Moves to Acquire Exact Sciences - Dark Daily
Abbott acquires Madison-based Exact Sciences in health care deal - The Daily Cardinal
Exact Sciences sale could benefit both companies, local economist says - The Cap Times
UBS Reaffirms Buy Rating on Abbott Laboratories (ABT) Amid Exact Sciences Acquisition - MSN
Stifel downgrades Exact Sciences stock rating to Hold following Abbott acquisition news - Investing.com India
Analysis of Abbott Laboratories (ABT.SW): Oversold Bounce Potential on the Swiss Exchange - Meyka
Will Abbott Laboratories stock maintain dividend yieldBond Market & Low Volatility Stock Recommendations - BỘ NỘI VỤ
Abbott Laboratories CEO warns tariffs are here to stay, points to new US investments [Video] - AOL.com
Abbott, Unity, Lowe’s, Vertiv, Roblox: Insider Moves Unveiled - TipRanks
Will Abbott Laboratories stock deliver consistent dividendsJuly 2025 Final Week & AI Optimized Trade Strategies - BỘ NỘI VỤ
How Analyst Views on Abbott Are Evolving as Its Growth Story Faces New Twists - Yahoo Finance
Aug Momentum: Is Abbott Laboratories stock a smart buy before Fed meetingQuarterly Portfolio Review & Free Risk Controlled Daily Trade Plans - moha.gov.vn
Abbott faces FLSA collective over alleged overtime pay calculations - HRD America
How Abbott’s Medical Device Advances Are Shaping Its 2025 Valuation Debate - simplywall.st
Abbott Accused Of Miscalculating Workers' Overtime - Law360
Assessing Abbott Laboratories (ABT) Valuation Following Steady 2024 Gains and Analyst Growth Projections - simplywall.st
Is Abbott Laboratories Stock Underperforming the S&P 500? - Barchart.com
Abbott Laboratories (ABT) Valuation in Focus After Renewed Trading Momentum - Yahoo Finance
Top Abbott Exec Cashes In on Stock Sale! - TipRanks
Insider Sell: Eric Shroff Sells Shares of Abbott Laboratories (A - GuruFocus
Abbott’s $23B Bet on Exact Sciences: Bold Move or Risky Gamble? - MedCity News
Abbott Laboratories SVP Shroff sells $203k in stock - Investing.com India
Abbott shares safety concerns with millions of CGM sensors—7 deaths reported - Cardiovascular Business
Abbott to replace glucose monitors after deaths possibly linked to false readings - Crain's Chicago Business
Abbott Laboratories Limited Appoints Brian William Jordan as A New Director, Effective November 25, 2025 - MarketScreener
Abbott issues correction over incorrect FreeStyle Libre sensor readings - Medical Device Network
Exact Sciences stock rating downgraded to Hold by TD Cowen following Abbott deal - Investing.com
Canaccord Genuity downgrades Exact Sciences stock to Hold after Abbott deal - Investing.com India
Abbott issues US device correction for some glucose monitors over faulty readings risk - WTVB
Abbott's Exact Sciences Acquisition Signals Maturation of Single-Site Specialty Dx Space - 360Dx
Abbott Laboratories Issues Correction on 3 Million Glucose Sensors Over Possible Faulty Readings - NTD News
Abbott mum on malfunction behind Freestyle Libre 3 recall - BioWorld MedTech
Abbott issues correction for millions of glucose sensors - MedTech Dive
Key facts: Abbott Labs to acquire Exact Sciences for $23 billion; recalls FreeStyle Libre 3 sensors - TradingView
Abbott issues medical device correction for some glucose monitors in U.S. - MarketScreener
Abbott is buying Exact Sciences. Here’s why - Modern Healthcare
Jefferies cuts Exact Sciences to 'hold' after Abbott acquisition - TradingView
Is Weakness In Abbott Laboratories (NYSE:ABT) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - Yahoo Finance
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.45%
4.20%
자본화:
|
볼륨(24시간):